DNAprint Genomics (DNAG)

[frogdreaming]

Gunna,
It is doubtful that DNAP is very happy that their option has transfered to Beckman Coulter. They have never announced the transfer publicly.

Remember that the option was granted in the deal that gave DNAP their first SNP evaluation system from Orchid. Orchid at that time was an instrument manufacturer as well as a forensic service organization.

DNAP's science is focused on developing products that lean in the direction of the service side of the Orchid's offerings. When Orchid sold it's instrument division to Beckman Coulter the associated option went with it. Unfortunately Beckman has much less of an interest in forensic products than Orchid does.

It is a less than optimum turn of events. Hopefully something good will come of it. Now that DNAP is on the verge of releasing their very first product developed on their own. (the hopefully imminent Retinome) the six month time window of the option can begin. The assumption of course is the window opens upon the release of the product and not when the associated patents are approved.

Beckman will have six months to decide whether to buy Retinome or pass, in which case the option will no longer be an issue in the development of the subsequent products. (Ovanome and Statinome).

regards,
frog